Early treatment with nonsucrose intravenous immunoglobulin in a burn unit reduces toxic epidermal necrolysis mortality.

摘要: BACKGROUND Intravenous immunoglobulin (IVIG) can be used to treat potentially deadly toxic epidermal necrolysis (TEN), milder Stevens Johnson Syndrome (SJS) and intermediate TEN/SJS overlap. Some formularies now deny IVIG for TEN based on the EuroSCAR study that reported a nonsignificant trend toward increased mortality in 75 IVIG-treated patients; of note patients had more less SJS than other treatment arms. data among 25 patients, use nonsucrose IVIG, admission specialized settings such as burn units was not disclosed. The impact setting (specialized unit vs general ward) efficacy has previously been studied. OBJECTIVE To evaluate treating with early unit. METHODS Data were retrospectively collected from 13 admitted over 6-year period. RESULTS We report 0% patients. Mortality significantly lower predicted by SCORTEN. also groups receiving (P<.005), supportive care (P<.018), corticosteroids only (P<.046). CONCLUSION may benefit administered or settings.